ObsEva Archives

Best in Biotech 18 May 2023

Six women’s health companies you should know about

While sexism exists in all strands of society, where in 2023, women earn 77 cents for every dollar earned by men, studies estimate that it will take the world 257 years to close the gender gap. And the global healthcare industry is partly to blame when it comes to the gaping gender gap. Women have […]

May 18, 2023 - 8 minutesmins - By Roohi Mariam Peter

More News! 10 Dec 2019

ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III

An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding and pain caused by uterine fibroids. The phase III trial tested ObsEva’s drug candidate linzagolix in 535 women suffering from heavy menstrual bleeding caused by benign tumors in the uterus called uterine fibroids. The effects of the drug were compared […]

December 10, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Feb 2018

Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy

Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban improved the pregnancy rate of women following in vitro fertilization. ObsEva, a clinical stage, Geneva-based biopharmaceutical company dedicated to women’s reproductive medicine, states that current Phase III results for the drug show an increase in pregnancy rate of 32 % after […]

February 27, 2018 - 2 minutesmins - By Alexander Burik

Interview 26 Jun 2017

Meet the Gynecologist at the Helm of Geneva’s Star Biotech

Ernest Loumaye began as a doctor at a university hospital and is now CEO of ObsEva. We chatted about how biotech supports women’s health. ObsEva, one of the top biotechs in Geneva that made this year’s first IPO for a huge €90M, is not Ernest Loumaye’s first company. Though he began as the gynecologist in charge of the reproductive […]

June 26, 2017 - 5 minutesmins - By Evelyn Warner

geneva biotech serono university of geneva

Best in Biotech 30 May 2017

In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight

Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […]

May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro

More News! 7 Mar 2017

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […]

March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us